Glucagonocentric restructuring of diabetes

A pathophysiologic and therapeutic makeover

Roger H Unger, Alan D. Cherrington

Research output: Contribution to journalArticle

342 Citations (Scopus)

Abstract

The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose- responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.

Original languageEnglish (US)
Pages (from-to)4-12
Number of pages9
JournalJournal of Clinical Investigation
Volume122
Issue number1
DOIs
StatePublished - Jan 3 2012

Fingerprint

Glucagon
Insulin
Therapeutics
Glucagon Receptors
Glucose
Metabolic Diseases
Leptin
Somatostatin
Ketones
Pancreas
Perfusion
Hormones
Liver
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glucagonocentric restructuring of diabetes : A pathophysiologic and therapeutic makeover. / Unger, Roger H; Cherrington, Alan D.

In: Journal of Clinical Investigation, Vol. 122, No. 1, 03.01.2012, p. 4-12.

Research output: Contribution to journalArticle

@article{e3f5f945947843b69879a4ef0aa06cf7,
title = "Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover",
abstract = "The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose- responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.",
author = "Unger, {Roger H} and Cherrington, {Alan D.}",
year = "2012",
month = "1",
day = "3",
doi = "10.1172/JCI60016",
language = "English (US)",
volume = "122",
pages = "4--12",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Glucagonocentric restructuring of diabetes

T2 - A pathophysiologic and therapeutic makeover

AU - Unger, Roger H

AU - Cherrington, Alan D.

PY - 2012/1/3

Y1 - 2012/1/3

N2 - The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose- responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.

AB - The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose- responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84855459920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855459920&partnerID=8YFLogxK

U2 - 10.1172/JCI60016

DO - 10.1172/JCI60016

M3 - Article

VL - 122

SP - 4

EP - 12

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -